A dose‐dense short‐term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high‐risk Burkitt lymphoma or high‐grade B‐cell lymphoma: safety and efficacy results of the “CARMEN” phase II trial-Reference-Cited by-同舟云学术

A dose‐dense short‐term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high‐risk Burkitt lymphoma or high‐grade B‐cell lymphoma: safety and efficacy results of the “CARMEN” phase II trial

Published:2020-10-21 Issue:1 Volume:192 Page:119-128
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Ferreri Andrés J. M.¹^ORCID,Cattaneo Chiara²,Lleshi Arben³,Verga Luisa⁴,Allione Bernardino⁵,Facchetti Fabio⁶,Ponzoni Maurilio⁷⁸,Foppoli Marco¹,Ferrari Daris⁹,Rigacci Luigi¹⁰,Pecciarini Lorenza⁷,Donadoni Giovanni¹,Fumagalli Luca¹¹,Sassone Marianna¹,Calimeri Teresa¹,Rossi Giuseppe²,Spina Michele³,Re Alessandro²

Affiliation:

1. Lymphoma Unit Department of Onco‐Hematology IRCCS San Raffaele Scientific Institute MilanItaly

2. Division of Hematology Ospedali Civili di Brescia BresciaItaly

3. Division of Medical Oncology and Immune‐related tumors IRCCS Centro di Riferimento Oncologico (CRO) Aviano (PN)Italy

4. Division of Hematology Azienda Ospedaliera San Gerardo MonzaItaly

5. A.O. Città della Salute e della Scienza ‐ Le Molinette TurinItaly

6. Pathology Unit Ospedali Civili di Brescia BresciaItaly

7. Pathology Unit IRCCS San Raffaele Scientific Institute MilanItaly

8. Vita‐Salute San Raffaele University MilanoItaly

9. Division of Medical Oncology Azienda Ospedaliera San Paolo MilanItaly

10. Division of Hematology Ospedale Careggi FlorenceItaly

11. Infectious Diseases Unit IRCCS San Raffaele Scientific Institute Milan Italy

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17188

Reference24 articles.

1. Characteristics and outcomes of HIV‐related Burkitt lymphoma (HIV‐BL) in the post‐rituximab era across 30 US cancer centers;Alderuccio JP;Haematologica,2020

2. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis

3. Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma

4. Revised Response Criteria for Malignant Lymphoma

5. Clinical Significance of MYC Expression and/or “High-grade” Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human immunodeficiency virus-associated lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Annals of Oncology;2024-10

2. Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up;HemaSphere;2024-09

3. A quinolinyl resveratrol derivative alleviates acute ischemic stroke injury by promoting mitophagy for neuroprotection via targeting CK2α’;International Immunopharmacology;2024-08

4. MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study;Blood Advances;2024-02-16

5. How I treat secondary CNS involvement by aggressive lymphomas;Blood;2023-11-23